Company Overview

Prosensa, part of the BioMarin family, is focused on the discovery, development and commercialization of RNA-modulating therapeutics.  Prosensa is a biopharmaceutical company focused on the discovery, development and commercialization of RNA modulating therapeutics. The company targets genetic disorders with a large unmet medical need, with a primary focus on neuromuscular and neurodegenerative disorders such as Duchenne Muscular Dystrophy (DMD)Myotonic Dystrophy (DM1) and Huntington's Disease (HD).

Prosensa's portfolio of clinical and pre-clinical RNA-based drug candidates is currently focused on the treatment of DMD, with 6 programs currently in development. Prosensa’s lead candidate for the treatment of DMD, drisapersen, has completed Phase III clinical trials. 

Prosensa commenced operations in 2002 and is located in Leiden, The Netherlands. The company works closely together with academia, patient groups and experts worldwide.  For more information, please go to

View all »   RSSRecent Releases

Feb 10, 2015
Prosensa Announces Voluntary Delisting and Advance Liquidation Distribution

Jan 30, 2015
Prosensa Announces Intent to Voluntarily Delist From NASDAQ